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a b s t r a c t
The cancer secretome includes all of the macromolecules secreted
by cells into their microenvironment. Cancer cell secretomes are
signiﬁcantly different to that of normal cells reﬂecting the changes
that normal cells have undergone during their transition to
malignancy. More importantly, cancer secretomes are known to be
active mediators of both local and distant host cells and play an
important role in the progression and dissemination of cancer.
Here we have quantitatively proﬁled both the composition of
breast cancer secretomes associated with osteotropism, and their
modulation under normoxic and hypoxic conditions. We detect
and quantify 162 secretome proteins across all conditions which
show differential hypoxic induction and association with osteo-
tropism. Mass Spectrometry proteomics data have been deposited
to the ProteomeXchange Consortium with the dataset identiﬁer
PXD000397 and the complete proteomic, bioinformatic and bio-
logical analyses are reported in Cox et al. (2015) [1].
& 2015 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Speciﬁcations table
Subject area Biology
More speciﬁc sub-
ject area
Breast Cancer, Bone Metastasis, Secretome
Type of data Mass Spectrometry RAW ﬁles
How data was
acquired
LC-MS/MS on a Q-Exactive Mass Spectrometer (Thermo Fisher Scientiﬁc)
Data format .RAW ﬁles
Experimental
factors
None applied
Experimental
features
The project proﬁled the expression patterns in hypoxia induced secretomes
between MDA-MB-231 parental and MDA-MB-231 Bone Tropic (BT) breast
cancer cell lines which have been previously generated by Massague and
colleagues (Kang et al. Cancer Cell 2003).
Data source
location
Copenhagen, Denmark
Data accessibility The Mass Spectrometry proteomics data for the article “The hypoxic cancer
secretome induces pre-metastatic bone lesions through lysyl oxidase”
doi:10.1038/nature14492 [1] have been deposited to the ProteomeXchange
Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE
partner repository [2] with the dataset identiﬁer PXD000397
Value of the data
 This data set will be of value to the scientiﬁc community wanting to determine which proteins are
secreted from breast cancer cells that metastasize to bone, and those that are regulated by hypoxia.
 The dataset includes quantitative global proteome (Label-free and SILAC) analysis of hypoxic
induced secretomes of parental and bone tropic human breast cancer cell lines.
 Differential analysis of secretome changes associated with bone tropism in breast cancer.
 Response of the cancer secretome to hypoxic induction.
1. Data, experimental design, materials and methods
1.1. Cell lines
The MDA-MB-231 Bone Tropic (BT) 1833 subclone cell line was obtained from J. Massagué at the
Memorial Sloan-Kettering Cancer Center. The MDA-MB-231 parental cell line was obtained from the
American Type Culture Collection (ATCC) (distributed by LGC Standards). All cell lines were routinely
tested for mycoplasma and tested negative for murine pathogens by IMPACT I testing (IDEXX
Laboratories).
1.2. Collection of hypoxia induced conditioned medium (CM)
For label-free Mass Spectrometry analysis, the MDA-MB-231 parental (wt) cell line and the MDA-
MB-231 Bone Tropic (BT) (1833 sub clone derived in Kang et al. [3]) (a kind gift from J. Massagué)
were routinely cultured in high glucose Dulbecco's Modiﬁed Essential Media (DMEM)þGlutaMAX
(Gibco 31966-021) with 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco 15140-122), plus 10%
dialysed Fetal Bovine Serum (FBS) (Gibco 26400). For conditioned media (CM) collection, cells were
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grown to 70% conﬂuence, washed with PBS and the media changed to serum-free DMEM and
incubated at either 21% oxygen, 5% CO2, 80% humidity (normoxia) or 1% oxygen, 5% CO2, 80% humidity
(hypoxia) for 24 h in a Whitley H35 Hypoxystation (Don Whitley Scientiﬁc Ltd.). After 24 h, the
conditioned media was collected and passed through a 0.22 μM ﬁlter to remove ﬂoating cells and
cellular debris.
For SILAC-based Mass Spectrometry, the MDA-MB-231 parental (wt) and MDA-MB-231 Bone
Tropic (BT) cell lines were both grown in light and heavy Stable Isotope Labelling of Amino Acids in
Culture (SILAC) DMEM with 100 U/ml penicillin and 100 μg/ml streptomycin, plus 10% dialysed Fetal
Bovine Serum (FBS). DMEM (Caisson Labs) lacking arginine and lysine was supplemented with
70 μg/mL light isotope 12C-,14N-arginine and 140 μg/mL light isotope 12C-,14N-lysine (Sigma) (R0/K0)
or 70 μg/mL heavy isotope 13C-,15N-arginine and 140 μg/mL heavy isotope 13C-,15N-lysine (Cambridge
Isotope Laboratories) (R10/K8). Cells were grown for 5 passages and label incorporation was assessed
through quantiﬁcation of the number of labelled vs. unlabelled peptides. A minimum of 97–98%
labelled arginine and lysine incorporation, with less than 1% proline conversion, was required for
subsequent proteomics studies. For conditioned media (CM) collection, cells were grown to 70%
conﬂuence, washed with PBS and the media changed to serum-free DMEM and incubated at either
21% oxygen, 5% CO2, 80% humidity (normoxia) or 1% oxygen, 5% CO2, 80% humidity (hypoxia) for 24 h
in a Whitley H35 Hypoxystation (Don Whitley Scientiﬁc Ltd.). After 24 h, the conditioned media was
collected and passed though a 0.22 μM ﬁlter to remove ﬂoating cells and cellular debris.
1.3. Preparation of CMs for Mass Spectrometry
After collection, label-free and SILAC-labelled CMs were reduced in volume using Vivaspin 6
10,000 MWCO, PES Membrane centrifugal concentrators (Sartorius). The remaining protein was fully
dissolved in 6 M urea, 2 M thiourea and 10 mM HEPES pH 8, after which exact protein amounts were
determined using a Bradford assay. In SILAC-labelled repeats, the two SILAC labels (R10/K8 and R0/K0)
were mixed 1:1. In label-free repeats, the samples were left unmixed, but equal amounts of starting
material were used for processing. Proteins were reduced in 1 mM DTT (Sigma) for 45 min at room
temperature (21 °C), alkylated for 45 min using 5.5 mM chloroacetamide (Sigma), and digested with
1:50 (enzyme:protein ratio) of Mass Spectrometry (MS)-grade trypsin (Sigma) overnight at 37 °C.
Peptides were acidiﬁed with triﬂuoroacetic acid at a ﬁnal concentration of 2%, after which they were
desalted on in-house packed C18 StageTips as previously described [4]. Brieﬂy, 2 discs of C18 material
(3 M Empore) were packed into a 200 μl pipette tip, and activated with 20 μl of Methanol (HPLC
grade) and 20 μl of 80% Acetonitrile, 0.1% FA. The C18 material was equilibrated with 220 μl of 1%
TFA, 3% Acetonitrile, after which 5 μg of each sample was loaded onto individual StageTips. After
washing with 220 μl of 0.1% FA, peptides were eluted with 240 μl 80% Acetonitrile, 0.1% FA, and
concentrated to 5 μl in an Eppendorf Speedvac. This ﬁnal concentrate was acidiﬁed with 4 μl 1% TFA,
2% Acetonitrile for Mass Spectrometry analysis.
1.4. Mass Spectrometry acquisition and analysis
5 μg of peptides were loaded onto a 50 cm C18 reverse-phase analytical column (Thermo Easy-
Spray ES803) using 100% Buffer A (0.1% Formic acid in water) at 720 bar, using the Thermo EasyLC
1000 uHPLC system in a single-column setup and the column oven operating at 45 °C. Peptides were
eluted over a 4 hour gradient ranging from 6 to 60% of 80% acetonitrile, 0.1% formic acid, and the Q-
Exactive (Thermo Fisher Scientiﬁc) was run in a DD-MS2 top10 method. Full MS spectra were col-
lected at a resolution of 70,000, with an AGC target of 3106 or maximum injection time of 20 ms
and a scan range of 300–1750 m/z. The MS2 spectra were obtained at a resolution of 17,500, with an
AGC target value of 1106 or maximum injection time of 60 ms, a normalised collision energy of 25
and an underﬁll ratio of 0.1%. Dynamic exclusion was set to 45 s, and ions with a charge state o2 or
unknownwere excluded. MS performance was veriﬁed for consistency by running complex cell lysate
quality control standards, and chromatography was monitored to check for reproducibility.
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2. Data processing protocol
Raw data were processed using MaxQuant version 1.5.0.0 [5] (using the human Ensembl GRCh38
database) and Perseus version 1.4. Results were analysed using scripts written in-house in Python and
R (deposited in the ProteomeXchange repository alongside data), and tested for statistical signiﬁcance
using the quantile function in the R statistical framework. To ensure high conﬁdence identiﬁcations
Fig. 1. (a) Overlaps between repeats of global secretome analysis in MDA-MB-231 parental and MDA-MB-231 Bone Tropic (BT)
cells grown in normoxic (21% O2) and hypoxic (1% O2) conditions. (b) Log2 expression levels under conditions of hypoxia (1%
O2) and normoxia (21% O2) for ﬁltered secreted proteins from the MDA-MB-231 parent and MDA-MB-231 Bone Tropic (BT)
1833 cell line. Data representative of 4 repeats, 2 label-free repeats, and 2 SILAC (standard and reverse-label) repeats. A full
list of plotted proteins and their expression levels can be found in Table 1.
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and quantiﬁcation, a MaxQuant score of 450 and a minimum of two unique peptides per protein
seen by tandem MS in all repeats were required. Initial analysis was undertaken using a label-free
approach (two repeats) for global pairwise analyses, and data subsequently validated in a standard-
and reverse-label SILAC approach (two repeats). Identiﬁed intracellular contaminants were removed
and secreted proteins retained by using the cellular compartment annotations in Ensembl and Pan-
therDB, and Gene Ontology annotation enrichment for extracellular-associated terms. Overlap
between global secretome Madd Spectrometry repeats in are shown in Fig. 1a for each condition. Log2
expression data of extracellular secreted proteins in pairwise analysis is shown in Fig. 1b. A full list of
detected proteins and their quantitative expression is available in supplementary Table 1. The com-
plete proteomic, bioinformatic and biological analyses are reported in Cox et al. (2015) [1].
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